Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2256294 Effects on Pulmonary Artery Pressure in Healthy Volunteers
NCT02262689Phase 1Completed
- Sponsor
- GSK
- Start
- Jan 2015
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) and pulmonary hypertension (PH) comparing GSK2256294 15 mg with Placebo (2 arms). Primary endpoint: Change from baseline of Pulmonary Artery Systolic Pressure under hypoxic conditions at Day 7. Started Jan 2015; status: completed.
02
Drugs
GSK2256294
03
Conditions
chronic obstructive pulmonary disease (COPD)pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT02262689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02262689.